Sio Gene Therapies Inc (fka SIOX)

[georgejjl]

“Dosing the first Type I patient represents a major milestone for the AXO-AAV-GM1 program and for the GM1 gangliosidosis community. The efforts by both Sio and our trial partners at the NIH are the culmination of our dedication to patients,” said Gavin Corcoran, M.D., Chief R&D Officer of Sio Gene Therapies. “We are excited to expand the age range of patients that have been dosed to address this more severe form of GM1 gangliosidosis, and we expect to report 12-month topline safety, biomarker, and clinical outcomes data from the Type II low-dose cohort of AXO-AAV-GM1 in October 2021.”

https://investors.siogtx.com/news-releases/news-release-details/sio-gene-therapies-announces-dosing-first-gm1-gangliosidosis

Good luck and GOD bless,